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CD59The complement system is composed of soluble factors in plasma that enhance or ‘‘complement’’
immune-mediated killing through innate and adaptive mechanisms. Activation of complement
causes recruitment of immune cells; opsonization of coated cells; and direct killing of affected cells
through a membrane attack complex (MAC). Tumor cells up-regulate complement inhibitory factors
– one of several strategies to evade the immune system. In many cases as the tumor progresses, dra-
matic increases in complement inhibitory factors are found on these cells. This review focuses on
the classic complement pathway and the role of major complement inhibitory factors in cancer
immune evasion as well as on how current protein engineering efforts are being employed to
increase complement ﬁxing or to reverse complement resistance leading to better therapeutic out-
comes in oncology. Strategies discussed include engineering of antibodies to enhance complement
ﬁxation, antibodies that neutralize complement inhibitory proteins as well as engineered constructs
that speciﬁcally target inhibition of the complement system.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The complement system and its regulation
For over a hundred years, the interaction of adaptive immunity
with a heat-labile serum component that ‘‘complements’’ cytotoxic
activity has been recognized [1]. In what is now deﬁned as the
‘‘classical pathway’’, antibody is bound to the surface of a cell
and recruits serum components that lead to cell killing and clear-
ance of pathogens [2]. Two other branches of complement are
now recognized: the ‘‘lectin pathway’’, in which signaling is initi-
ated by binding to certain polymeric molecules and carbohydrates;
and the ‘‘alternate pathway’’, where cells that are not host speciﬁc
are destroyed due to the lack of inhibitory factors. This pathway
initially was thought to be constitutive, but recent research sug-
gests it is also triggered through speciﬁc binding interactions
[3,4]. The separation into these three cascades is somewhat artiﬁ-
cial: in response to various signals complement activation is
orchestrated by a network of interactions allowing elegant distinc-
tion of healthy host cells from debris, foreign intruders, and apop-
totic cells. A description of these speciﬁc interactions is beyond the
scope of this review and the reader is referred to other excellent
articles on the complement system [5,6].
Central to the activation of the complement system is the activity
of C3 which is cleaved into active forms C3a and C3b by C3 conver-
tases. Deposition of C3b on cell surfaces and its association witheither factor B or the C4bC2a complex leads to further activation of
complement throughC3conversionaswell as initiationof the termi-
nal complement cascade and formation of the membrane attack
complex [7–9]. In concert, the other products of C3 and C5 cleavage,
the anaphylatoxins C3a and C5a, have numerous other signaling
activities. They generate pro-inﬂammatory signals, increase vascu-
lar permeability, and stimulate phagocytosis [3,6]. Through comple-
ment receptors, inﬂammatory cytokines, and in conjunction with
TLR pathways, the products of C3 and C5 cleavage inﬂuence B cell
maturation, antigen presenting cell activation, and T cell inﬂux pro-
viding a bridge to adaptive immunity [10–14].
To prevent uncontrolled ampliﬁcation of the effects of comple-
ment there are a variety of complement regulatory proteins (CRPs).
These include soluble factors like C1 inhibitor, factor H, factor I,
and vitronectin as well as membrane-bound complement regula-
tory proteins (mCRPs) like CD35, CD46, CD55, and CD59. Tables
1A and 1B summarize major complement regulators and their
functions. Because of the high levels of serum complement pro-
teins that range into the high hundreds of milligrams per liter
[15], it is unlikely that cancerous growths could inﬂuence the sol-
uble complement protein balance. Tumors that evade comple-
ment’s action therefore appear to do so by modulating the levels
of the membrane bound components. In addition to direct inhibi-
tion of the complement system, these inhibitor can also inﬂuence
cellular and humoral immune responses [16,17] and eliminating
this inhibition can enhance cellular immunity, with key implica-
tions for cancer immune therapy [18].
Table 1A
Soluble complement regulatory factors.
Regulator Function
C1 inhibitor Serine protease that targets the C1s/C1r, inhibiting activation of C4 and C2 [19]
Factor H Modulates C3b formation by acting as a co-factor for Factor I and by accelerating the decay of the C3 convertases [20]
Factor I (C3b/C4b inactivator) Decreases complement activation by cleaving C3b and C4b when complexed with co-factors such as CD46 [21,22]
C4 Binding Protein (C4BP) A co-factor for Factor I, binds C4b increasing proteolytic accessibility [23]
Vitronectin (S40) Inhibits the terminal cascade and formation of the MAC; may have other roles in regulation of disease responses [24–26]
Clusterin (Apo J) Similar to vitronectin, inhibits the formation of the MAC and may have other functions [26]
Table 1B
Membrane-bound complement regulatory factors.
Regulator Function
CD35 (complement receptor 1, CR1) Decay accelerating factor for C3/C5 convertases, facilitates phagocytosis of
cells with complement activated, co-factor for Factor I, ﬁxes complement
immune complexes on erythrocytes, has limited tissue distribution in humans [27]
CD46 (membrane cofactor protein, MCP) Cofactor for factor I, regulator of T-cell differentiation and apoptosis, widely
expressed in humans [16,28,29]
CD55 (decay accelerating factor, DAF) Inhibits formation and accelerates decay of C3 convertases [30–32]
CD59 (MAC inhibitory protein, MAC-IP,
20 kDa homologous restriction factor, HRF20)
Inhibits formation of the MAC by binding C5b/8 complex and interfering with insertion of C9 [33,34]
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In the development of immune therapies for cancer the role of
complement has often been neglected, but asmore insight is gained
into the mechanisms of action of monoclonal antibodies new ap-
proaches to improve speciﬁc antibody functions are emerging.
Monoclonal antibodies have contributed substantially to progress
in treating many types of cancers, but tumors evasion mechanisms
lead to low complete response rates for many of these therapies
[35–38]. For example, rituximab is a humanized IgG1 antibody
against the surface protein CD20 which is expressed on the surface
of normal B-lymphocytes and B-cell malignancies but not on hema-
topoietic stemcells andplasmacells. It is currentlyused for the treat-
ment of B-cell non-Hodgkin lymphoma, mantle cell lymphoma,
hairy cell leukemia, and chronic lymphocytic leukemia. Survival
rates for B cell non-Hodgkin’s lymphoma have increased signiﬁ-Table 2
Complement regulatory proteins and documented increases in expression.a
Tissue type CD46 CD55
Lung cancers Consistent high levels found Low levels on few
Breast cancer Expressed in all breast carcinoma and
normal tissue examined, increase
associated with poor prognosis
No staining on ca
in ductal carcino
Colorectal cancer Strong increase in staining found on
most samples
None found
Prostate cancer Expressed but does not increase Increase in cance
with malignancy
Bladder cancer Upregulation up to around 10 fold in
77% of samples tested
Upregulation up
fold in 55% of sam
Malignant endometrial
tissue
2.5 fold rise in optical density on
stained image
2.2 fold rise in op
on stained image
Head and neck cancer Highly expressed in all forms, low to
no staining in normal surrounding
tissue
Highly expressed
no staining in no
tissue
Esophageal cancer Dramatic increase in staining Pronounced decr
Non-Hodgkin’s
lymphomab
High level expression with possible
correlation to outcome
High level expres
correlation to ou
Renal cell cancers Low, scattered staining No staining detec
Primary gynecologic
carcinosarcoma
High level expression High level expres
Ovarian cancer Robust expression on the surface of
cells
Robust expressio
cells
a No information is usually found on CD35 so this mCRP is not presented.
b The conclusions in the two papers contradict as to correlation with outcome; high lcantly since the introduction of rituximab, but only about half of
the patients suffering from this disease survive ten years after diag-
nosis. Thecancer recurs andpatientsoftenbecomeresistant to ritux-
imab therapy.Oneof themechanismsof actionof rituximab involves
binding tomalignant B-cells with subsequent activation of the com-
plement system [39–43]. By inhibiting the action of complement,
cancer cells could be able to evade killing by rituximab.
Overexpression of complement inhibitory proteins is awell-doc-
umented phenomenon in cancer cells and has been proposed as an
escapemechanism frommonoclonal antibody therapy [44–46]. This
up-regulation blocks complement signaling and allows cells with
boundantibody to evadekillingby the complement system. Thepat-
tern of complement inhibition is diverse for many different types of
tumors, stagesof tumorand canexceedmanyorders ofmagnitudeof
overexpression versus primary, normal tissue. That being said, the
levels of complement inhibitory proteins do not necessarily corre-CD59 Cit.
tumors Variable levels detected on majority of
cancers
[50]
ncer cells
mas
Trend towards increase in staining versus
normal tissues; variable on some patient
samples
[50–52]
Increase in staining, variable for some
samples
[51]
r and further Expressed, but does not increase [53]
to around 10
ples tested
Upregulation up to around 10 fold in 59% of
samples tested
[54]
tical density 1.7 fold rise in optical density on stained
image
[55]
in all forms, low to
rmal surrounding
Highly expressed in all forms, low to no
staining in normal surrounding tissue
[56]
ease in staining Uniform between normal and cancer tissue [57]
sion with possible
tcome
High level expression with possible
correlation to outcome
[58,59]
ted High levels on most tumors tested [50]
sion High level expression [60]
n on the surface of Robust expression on the surface of cells [61]
evels were found in both studies.
Fig. 1. Protein engineering targeting the Fc region to enhance complement ﬁxation. The ﬁgure shows the crystal structure of a human IgG1 (PDB: 1HZH, [83]) with the heavy
chain constant domains 2 in red. The rest of the heavy chain trace is in blue and light chains are shown in yellow. The long ﬂexible hinge regions allow for contact and binding
of the C1q complement components in the region labeled in the ﬁgure. Residues that have been reported to be important in the interaction with C1q and that have been
targeted by mutagenesis to modulate complement ﬁxation are shown with the full sidechains in green [64,84]. Protein was visualized with the Swiss-PdbViewer version 4.1.0
[85] and rendered using POV-Ray [86].
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shown with neutralizing antibodies, even low level expression of
individual CRPs is sufﬁcient to protect tumors from lysis induced
by monoclonal therapeutics [47–49].
Although by no means an exhaustive summary of all literature
on mCRPs in cancer, Table 2 shows how widespread enhancement
of surface expression of major membrane bound complement
inhibitory proteins is in cancers.Fig. 2. Engineering of the adenoviral ﬁber knob as an adjunct therapy to remove complem
from the vertices of the icosahedron. The knob portion of the adenovirus interacts with th
the Ad35 ﬁber knob regions interacting with CD46. The trimeric knob region used to gene
domains are in blue. Residues that were mutated and found to have effects on binding
structure from Fabry et al. [87] was used and rendered using Jmol [88] and POV-Ray [86
packages were used in Panel B, using the CD46/knob structure reported as PDB 2O39 [83. Engineering antibodies to more efﬁciently ﬁx complement
Because of the ability of tumor cells to evade complement-
dependent killing there have been multiple efforts to engineer
antibodies to increase the efﬁciency of complement ﬁxation and
thereby enhance complement dependent cell cytotoxicity (CDC).
Examining the mechanism of C1q binding that initiates the depo-
sition of complement in the classical pathway, one can envisionent inhibition. Panel A: Adenoviruses are icosahedral particles with ﬁbers extending
e virus receptor on the host cell and allows for viral entry. Panel B: Close up of one of
rate Ad35K++ is shown in red; the ﬁber shaft regions in yellow and the bound CD46
of CD46 [80] are shown with full sidechains in yellow. For Panel A the adenovirus
] after adding ﬁber knobs modeled in the Swiss-PDBViewer [85]. The same software
9] and the adenovirus ﬁber protein in PDB: 1QIU [90].
D. Carter, A. Lieber / FEBS Letters 588 (2014) 334–340 337that numerous approaches could be successful: (1) targeting high-
density membrane localized epitopes to increase the number of
bound antibodies per cell; (2) positioning the antibody binding site
so that it is membrane proximal and increases the efﬁciency of
membrane deposition of complement components; (3) increasing
the antibody’s afﬁnity to the target by reducing the off rate so that
it remains on the cells for a prolonged time; and (4) increasing the
interaction of the antibody with C1q. The ﬁrst three approaches are
embodied in the anti-CD20 antibody, ofatumumab or ‘‘Arzerra’’
that was intended to be an improvement over rituximab. Ofatumu-
mab was found to have a longer off-rate than the competitor and
the unique localization of the epitope near the surface of the cell
membrane is thought to enhance deposition of complement on
the membrane [62]. These complement enhancing features trans-
late into an enhancement of killing of complement resistant cells
from 25% (rituximab) to 75% (ofatumumab) [63].
Other protein engineering efforts focus primarily on the interac-
tion between the ﬁrst component of complement, C1, and the Fc
region of the target antibody. In this approach, either speciﬁc iso-
types known to ﬁx complement better are chosen as an antibody
scaffold or key Fc residues are mutated to promote favorable ener-
getics of binding between the Fc region of the antibody and the0
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Fig. 3. Using engineered knob proteins to enhance killing of lymphoma cells. Panel A
protein Ad35K++ as reported in Wang et al. [81]. NHS is used as source of complemen
Ad35K++ (1) is a protein lot that was produced previously and used in published studi
rituximab + NHS and Ad35K++ + rituximab + NHS is signiﬁcant (P < 0.01). The difference
signiﬁcant.complement component C1q. Fig. 1 shows key amino acids that
have been targeted when modulating antibody/C1q interactions
[64,65]. Modifying these speciﬁc amino acids can lead to dramatic
increases in C1q binding and enhance the potency of antibodies as
much as 600 fold [64,66].
4. Protein engineering to target complement inhibition
Although enhanced ﬁxation of complement is potentially
attractive for increasing CDC, complement inhibitors could elimi-
nate any beneﬁt by rapidly quelling complement triggering. For
this reason, engineering efforts targeting complement inhibition
could dramatically improve therapy and would ‘‘complement’’
antibody engineering efforts described in the previous section. Ef-
forts to target complement inhibition by knocking down mCRP
expression using siRNA have been successful [67,68], but we will
focus on protein-based engineering strategies here.
The most straightforward engineering approach is to make anti-
bodies that inhibit the function of the complement inhibitory pro-
teins. Ziller and colleagues screened a human antibody phage
display library for recognition of CD55 and CD59 and used the po-
sitive clones as variable chain templates that were fused to the)   rituximab   
NHS
Ad35K++(1)   
rituximab   
NHS
Ad35K++ (2)   
rituximab   
NHS
30min
Normal 
human 
serum (NHS)
3 hours
Cell viability
ls
)   rituximab   
NHS
Ad35K++(1)   
rituximab   
NHS
Ad35K++ (2)   
rituximab   
NHS
cells
– Experimental setup. Lymphoma cells were incubated with the engineered knob
t. Panel B – Both research and scaled preparations have equivalent efﬁcacy. N > 6.
es. Ad35K++ (2) is a protein made with a scalable process. The difference between
between Ad35K++ (1) + rituximab + NHS and Ad35K++ (2) + rituximab + NHS is not
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‘‘minibodies’’ MB55 (anti-CD55) and MB59 (anti-CD59) [69]. Using
rituximab combined with MB55 and MB59 enabled the researchers
to enhance survival of LCL2 challenged SCID mice from 30% to 70%.
Notably in this experiment, the MB55/MB59 combination without
rituximab was as effective as rituximab in enhancing survival [46].
Intermedilysin is a bacterial cytotoxin isolated from Streptococ-
cus intermedius that binds to CD59 and initiates pore formation in
human cells resulting in cell death [70]. The protein has a mem-
brane attack complex/perforin fold (MACPF) region that is respon-
sible for pore formation on the surface of the affected cell, and a
‘‘domain 4’’, an avid CD59 binding region [71]. By removing the
pore and linker domains and leaving only domain 4, Qin and Hu
et al. were able to generate a 114 amino acid, afﬁnity-tagged, re-
combinant protein that inhibited CD59 function, ‘‘rILYd4’’ [72].
This protein was then further engineered by removing the afﬁnity
tag to give a well behaved lead candidate targeting CD59 [73].
When rILYd4 was used in combination with CD20 targeted mono-
clonal antibodies for cancer, a dose dependent increase in cytolysis
was determined with the pretreatment allowing more than double
the amount of cell killing of rituximab resistant cells by both ritux-
imab and ofatumumab [74,75].
In another approach, the discovery that certain group B adeno-
viruses, including serotype 35, can interact with CD46 and lead to
its internalization and degradation [76,77] combined with the fact
that high levels of CD46 were found on tumors [78] led to the
hypothesis that adjuvanting antibody therapy with adenovirus-de-
rived removal of complement inhibition would be a viable clinical
path to improve cancer therapy. Simply infusing large amounts of
adenovirus would be impractical so that an engineered protein was
sought to develop a therapeutic candidate. The ideal candidate
would be a relatively small protein that could penetrate tumors
and be straightforward to manufacture, as well as having high
binding afﬁnities for the inhibitory target. Adenoviruses display ﬁ-
ber proteins that extend out from each vertix of the virus and inter-
act with the virus’ receptor (Fig. 2). The receptor binding domain is
localized in the C-terminal domain of the trimeric ﬁber and is
called the ﬁber knob. The adenovirus serotype 35 knob protein
has two CD46 contacting loops and due to the trimeric knob pro-
tein structure makes high avidity contacts when bound to CD46.
This coding region for a functional Ad35knob protein end was in-
serted into an Escherichia coli expression vector and mutated by er-
ror prone PCR [79,80] resulting in high afﬁnity variants; individual
mutations at knob protein positions 207, 245, and 256 (Fig. 2B) re-
sulted in up to 8 fold increases in afﬁnity and combined mutations
resulted in a lead candidate protein, Ad35K++, with a drop from 14
nanomolar dissociation constants down to 630 picomolar KD’s, an
increase in afﬁnity of more than 23 fold. This new construct was
then tested for its ability to enhance rituximab killing of lymphoma
cells in vitro and was found to dramatically enhance complement
dependent killing (Fig. 3 and [81]). In later in vivo studies the com-
bination of rituximab and Ad35K++ markedly increased responses
to lymphoma xenographs in mice and sensitized non-human pri-
mate CD20 positive B-cells to the action of rituximab after intrave-
nous injection into macaques [82].5. Translational development of anti-complement therapies
Clinical testing and commercial deployment of new proteins
targeting complement inhibition in cancer will require efﬁcient
manufacturing processes that comply with regulatory require-
ments. Once the concept of reversing complement inhibition in
cancer is successfully proven in pre-clinical models, the focus
should be on how to achieve the same results with a commercial-
izable production process (e.g., as demonstrated in Fig. 3). Investi-gators engineering proteins as adjunct therapies that sensitize to
the action of approved drugs such as monoclonals in cancer should
keep in mind the development issues that such a product faces:
costs need to be reduced to ensure that the combination product
has an attractive commercial proﬁle.
Enhanced immune effector functions may increase toxicological
concerns and deciding on viable administration doses and timings
is a complex pharmacokinetic and pharmacodynamic problem. In
addition, off-target neutralization of complement inhibition could
lead to undesirable triggering of complement responses that dam-
age healthy cells and organ systems. To address this, new ways to
target the therapeutic to tumor cells could be required – especially
if these cells have the same redundancy in complement inhibitory
proteins found on normal cells and requiring neutralization of mul-
tiple CRPs. Nonetheless, the broad applicability of a successful co-
immunotherapeutic makes this strategy highly relevant for the
treatment of cancer patients.
6. Conclusion
The complement pathway may have been underappreciated in
terms of how important evasion may be to tumor cell survival.
Both direct killing of cells as well as recruitment of cellular effec-
tors can be initiated by complement and there is a strong body
of literature supporting the fact that cancers up-regulate comple-
ment inhibitory factors. Innovative protein engineering efforts
have co-opted natural protein inhibitors of complement inhibition
and utilized these to target tumor cells. Genetic engineering strat-
egies made small, commercially-deployable proteins with very
high afﬁnity for membrane associated complement regulatory pro-
teins. Preclinical testing of these molecules offers hope that the
dramatic effects in animal models may be recapitulated in human
trials. Successful completion of these trials may open the gate to a
new line of protein therapies and a revolution in cancer immune
therapy.
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